JP2018501195A - 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 - Google Patents

脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 Download PDF

Info

Publication number
JP2018501195A
JP2018501195A JP2017524040A JP2017524040A JP2018501195A JP 2018501195 A JP2018501195 A JP 2018501195A JP 2017524040 A JP2017524040 A JP 2017524040A JP 2017524040 A JP2017524040 A JP 2017524040A JP 2018501195 A JP2018501195 A JP 2018501195A
Authority
JP
Japan
Prior art keywords
group
mice
mes
high fat
fat diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017524040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501195A5 (cg-RX-API-DMAC7.html
Inventor
ヨンチャン、ルオ
ホイ、ワン
ホイ、リー
シンアン、ルー
ヤン、フー
シュンリ、ジャン
ダイフ、チョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of JP2018501195A publication Critical patent/JP2018501195A/ja
Publication of JP2018501195A5 publication Critical patent/JP2018501195A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017524040A 2014-11-03 2015-11-03 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 Pending JP2018501195A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777 2014-11-03
CN201410610777.X 2014-11-03
CN201510021469.8 2015-01-15
CN201510021469 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020126891A Division JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Publications (2)

Publication Number Publication Date
JP2018501195A true JP2018501195A (ja) 2018-01-18
JP2018501195A5 JP2018501195A5 (cg-RX-API-DMAC7.html) 2018-12-13

Family

ID=55908589

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017524040A Pending JP2018501195A (ja) 2014-11-03 2015-11-03 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物
JP2020126891A Active JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020126891A Active JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Country Status (7)

Country Link
US (2) US20180015148A1 (cg-RX-API-DMAC7.html)
EP (1) EP3246043A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018501195A (cg-RX-API-DMAC7.html)
CN (2) CN114558111A (cg-RX-API-DMAC7.html)
AU (1) AU2015342324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3003760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016070798A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507854A (ja) * 2015-02-13 2018-03-22 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115721730B (zh) 2016-11-10 2025-03-14 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502814A (ja) * 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002323543A1 (en) * 2001-09-07 2003-03-24 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
BRPI0819434A2 (pt) * 2007-11-08 2019-09-24 Univ Utah Res Found método de tratamento ou prevenção de doenças hepáticas e uso de antagonistas á angiogênese em condições de proliferação venosa anormal
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
AU2012236199A1 (en) * 2011-03-30 2013-09-26 Board Of Regents Of The University Of Texas System Methods and compositions for targeting adipose cells in mammals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502814A (ja) * 1997-10-31 2002-01-29 チルドレンズ・メディカル・センター・コーポレイション 血管化した正常組織の大きさおよび増殖の調節のための方法
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"化学物質による脂肪肝", 日本臨床（別冊）新領域別症候群シリーズNO.13 肝・胆道系症候群（第２版） Ｉ 肝臓編（上）, JPN6019043961, pages 196 - 201, ISSN: 0004239777 *
EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 239, no. 8, JPN6019043959, August 2014 (2014-08-01), pages 998 - 1006, ISSN: 0004239776 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507854A (ja) * 2015-02-13 2018-03-22 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計

Also Published As

Publication number Publication date
US20180015148A1 (en) 2018-01-18
WO2016070798A1 (zh) 2016-05-12
CA3003760A1 (en) 2016-05-12
CN107148277A (zh) 2017-09-08
CN114558111A (zh) 2022-05-31
EP3246043A4 (en) 2018-09-05
JP7227197B2 (ja) 2023-02-21
EP3246043A1 (en) 2017-11-22
AU2015342324B2 (en) 2021-08-19
EP3246043A9 (en) 2018-03-14
JP2020172546A (ja) 2020-10-22
CN107148277B (zh) 2022-03-22
AU2015342324A1 (en) 2017-06-29
US20220409703A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
Yu et al. Adipocyte-derived exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPARγ
US20220409703A1 (en) Drug for inhibiting adipose cell differentiation and insulin resistance
Song et al. γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells
Roy et al. Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator–activated receptor γ (PPARγ) during adipocyte differentiation
Tu et al. Cardiolipin synthase 1 ameliorates NASH through activating transcription factor 3 transcriptional inactivation
Guo et al. Cystathionine γ‐lyase deficiency aggravates obesity‐related insulin resistance via FoxO1‐dependent hepatic gluconeogenesis
Huang et al. Rab9‐dependent autophagy is required for the IGF‐IIR triggering mitophagy to eliminate damaged mitochondria
Chen et al. Role of sphingosine-1-phosphate receptor 1 and sphingosine-1-phosphate receptor 2 in hyperglycemia-induced endothelial cell dysfunction
CN110538327A (zh) Gpr31抑制剂在制备治疗脂肪代谢异常及相关疾病的药物中的应用
Ding et al. Adiponectin protects rat heart from left ventricular remodeling induced by chronic intermittent hypoxia via inhibition of TGF-β/smad2/3 pathway
Li et al. Suppression of the expression of hypoxia-inducible factor-1α by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats
Liu et al. Toona sinensis ameliorates insulin resistance via AMPK and PPARγ pathways
Gao et al. Schisandrin A protects against isoproterenol-induced chronic heart failure via miR-155
Shi et al. LncRNA-MALAT 1 regulates cardiomyocyte scorching in diabetic cardiomyopathy by targeting NLRP3
Hou et al. Taurine transporter regulates adipogenic differentiation of human adipose-derived stem cells through affecting Wnt/β-catenin signaling pathway
Yoon et al. Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3-L1 preadipocytes via AKT/mTOR pathway
Jeong et al. Modulation of the expression of sphingosine 1-phosphate 2 receptors regulates the differentiation of pre-adipocytes
CN110592222A (zh) Triml1作为肝癌的分子标记物的应用
Yuan et al. Aldehyde dehydrogenase 2 protects against sympathetic excitation-induced cardiac fibrosis
Liu et al. Cloning and characterization of adipogenin and its overexpression enhances fat accumulation of bovine myosatellite cells
Wang et al. MicroRNA-532-5p upregulation protects neurological deficits after ischemic stroke through inhibition of BTB and CNC homology 1
Lv et al. Downregulation of miR-20b-5p contributes to the progression of liver fibrosis via the STAT3 signaling pathway in vivo and in vitro
Kim et al. GDF15 inhibits early-stage adipocyte differentiation by enhancing HOP2 expression and suppressing C/EBPα expression
JP2011055755A (ja) Ｍｘｄ３遺伝子の発現阻害による肥満の抑制
Su et al. Molecular characterization of vascular endothelial growth factor b from spotted sea bass (Lateolabrax maculatus) and its potential roles in decreasing lipid deposition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200324